Search for Clinical Trial Results
Medulloblastoma - 50 Studies Found
Status | Study |
Recruiting |
Study Name: Study of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma Condition: High-risk Medulloblastoma Date: 2013-12-30 Interventions:
|
Completed |
Study Name: Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma Condition: Recurrent Childhood Medulloblastoma Date: 2010-11-10 Interventions:
|
Not yet recruiting |
Study Name: Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma Condition: Untreated Childhood Medulloblastoma Date: 2016-03-25 Interventions:
|
Completed |
Study Name: Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-Metastatic Desmoplastic Medulloblastoma Condition: Untreated Childhood Medulloblastoma Date: 2013-12-13 Interventions:
|
Completed |
Study Name: GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment Condition: Recurrent Childhood Medulloblastoma Date: 2009-01-13 Interventions:
|
Completed |
Study Name: Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma Condition: Untreated Childhood Medulloblastoma Date: 2004-06-14 Interventions:
|
Withdrawn |
Study Name: A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma Condition:
Date: 2012-09-28 Interventions:
|
Recruiting |
Study Name: Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway Condition:
|
Recruiting |
Study Name: Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor Condition:
Date: 2010-07-22 Interventions:
|
Terminated |
Study Name: Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma Condition:
Date: 2011-11-28 Interventions: Drug: TPI 287 Subjects will receive six cycles of intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Day |